In a study on pancreatic cancer, Alexander lux et al. used immunocytochemistry and FCM to explore the feasibility of circulating exosomal c-Met and PD-L1 as markers for the diagnosis and poor prognosis of pancreatic cancer [37]. This evidence concerns the gene MET and familial pancreatic carcinoma.